ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Overview
USA - NASDAQ:ARCT - US03969T1097 - Common Stock
ARCT Key Statistics, Chart & Performance
The current stock price of ARCT is 10.59 USD. In the past month the price decreased by -43.61%. In the past year, price decreased by -41.17%.
ARCT Latest News, Press Relases and Analysis
ARCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.83B | ||
| AMGN | AMGEN INC | 13.35 | 156.75B | ||
| GILD | GILEAD SCIENCES INC | 15.56 | 149.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 107.73B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 62.04B | ||
| ARGX | ARGENX SE - ADR | 90.1 | 51.09B | ||
| INSM | INSMED INC | N/A | 34.67B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.08 | 34.65B | ||
| NTRA | NATERA INC | N/A | 26.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.49B | ||
| BIIB | BIOGEN INC | 9.4 | 22.05B |
Related stock screener links
About ARCT
Company Profile
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Company Info
ARCTURUS THERAPEUTICS HOLDIN
10628 Science Center Dr Ste 250
San Diego CALIFORNIA 92121 US
CEO: Joseph E. Payne
Employees: 174
Phone: 18589002660
ARCTURUS THERAPEUTICS HOLDIN / ARCT FAQ
Can you describe the business of ARCTURUS THERAPEUTICS HOLDIN?
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
What is the stock price of ARCTURUS THERAPEUTICS HOLDIN today?
The current stock price of ARCT is 10.59 USD. The price decreased by -5.61% in the last trading session.
Does ARCT stock pay dividends?
ARCT does not pay a dividend.
How is the ChartMill rating for ARCTURUS THERAPEUTICS HOLDIN?
ARCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock traded?
ARCT stock is listed on the Nasdaq exchange.
What is the ownership structure of ARCTURUS THERAPEUTICS HOLDIN (ARCT)?
You can find the ownership structure of ARCTURUS THERAPEUTICS HOLDIN (ARCT) on the Ownership tab.
What is the Short Interest ratio of ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?
The outstanding short interest for ARCTURUS THERAPEUTICS HOLDIN (ARCT) is 21.22% of its float.
ARCT Technical Analysis
ARCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARCT. While ARCT has a great health rating, there are worries on its profitability.
ARCT Financial Highlights
Over the last trailing twelve months ARCT reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 13.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.45% | ||
| ROE | -26.04% | ||
| Debt/Equity | 0 |
ARCT Forecast & Estimates
17 analysts have analysed ARCT and the average price target is 66.07 USD. This implies a price increase of 523.92% is expected in the next year compared to the current price of 10.59.
For the next year, analysts expect an EPS growth of 13.39% and a revenue growth -44.89% for ARCT